108 related articles for article (PubMed ID: 33370021)
21. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
22. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
23. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
Czosnyka NM; Borgert AJ; Smith TJ
HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
[TBL] [Abstract][Full Text] [Related]
25. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; Yu J; Borel Rinkes IHM; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Eur J Surg Oncol; 2019 Sep; 45(9):1674-1683. PubMed ID: 31023560
[TBL] [Abstract][Full Text] [Related]
26. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
[TBL] [Abstract][Full Text] [Related]
27. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
[TBL] [Abstract][Full Text] [Related]
28. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer.
Sunagawa Y; Yamada S; Sato Y; Morimoto D; Sonohara F; Takami H; Inokawa Y; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Ann Surg Oncol; 2020 Jun; 27(6):2081-2089. PubMed ID: 31673938
[TBL] [Abstract][Full Text] [Related]
29. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.
Tzeng CW; Balachandran A; Ahmad M; Lee JE; Krishnan S; Wang H; Crane CH; Wolff RA; Varadhachary GR; Pisters PW; Aloia TA; Vauthey JN; Fleming JB; Katz MH
HPB (Oxford); 2014 May; 16(5):430-8. PubMed ID: 23991810
[TBL] [Abstract][Full Text] [Related]
30. Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review.
Watanabe Y; Nishihara K; Matsumoto S; Okayama T; Abe Y; Nakano T
Surg Today; 2017 May; 47(5):555-567. PubMed ID: 27704248
[TBL] [Abstract][Full Text] [Related]
31. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis.
Uchida Y; Masui T; Nagai K; Anazawa T; Yoshimura M; Uza N; Takaori K; Mizowaki T; Uemoto S
Surg Oncol; 2020 Dec; 35():527-532. PubMed ID: 33160278
[TBL] [Abstract][Full Text] [Related]
32. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
[TBL] [Abstract][Full Text] [Related]
33. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy.
Aoyama T; Atsumi Y; Kazama K; Murakawa M; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1129-S1134. PubMed ID: 30539858
[TBL] [Abstract][Full Text] [Related]
34. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
35. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
[TBL] [Abstract][Full Text] [Related]
37. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
38. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
39. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
40. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]